Table 1.

Characteristics of analyzed sample (n=944)

Characteristics	Unweighted			Weighted
	Mean	SD	%	Mean	SE	%
Self-reported PET scans (at least one) at round 3			10.6			10.5
Self-reported PET scans (at least one) at round 2			11.1			11.0
Seeking from non-medical sources at round 2	0.0	0.5		0.0	0.0
Patient-clinician information engagementat round 2	0.0	0.6		0.0	0.0
Age at cancer diagnosis (years)	65.3	11.4		67.7	0.5
Gender – Female			51.1			51.4
Education – Some college and above			50.8			49.6
Race/ ethnicity
White			85.4			86.6
Black			11.3			8.5
Hispanic or other			3.3			4.9
Marital status – Married			70.7			59.4
Cancer type
Colon cancer (male)			13.8			13.6
Colon cancer (female)			14.9			15.2
Breast cancer			36.1			36.2
Prostate cancer			35.2			35.0
Type of treatment received
Surgery			74.2			71.7
Radiation therapy			51.1			50.9
Systemic therapy (Chemotherapy or hormonal therapy)			49.6			47.6
Health status at round 2a	3.3	0.9		3.3	0.0
Cancer stageb
Stage 0–II			82.4			82.1
Stage III			10.8			10.6
Lerman Cancer Worry at round 2c	6.8	2.8		6.5	0.1
Followed doctor’s recommendations about cancer follow up tests at round 2d	4.5	0.9		4.4	0.7
Frequency of doctor visits at round 2e	2.6	0.9		2.5	0.0
Concern about reducing the chance of cancer recurrence at round 2 – Yes			68.3			68.3

Notes:

^aRanged from 1 ‘Poor’ to 5 ‘Excellent’;

^bCancer stage was assessed at time of diagnosis and was categorized into 0-II and III because prostate cancer patients in this population were all diagnosed at stage II or above—this did not influence the substantive results for the analysis;

^cRanged from 3 to 15 (sum of 3 items with responses ranging on a 5-point scale from ‘not at all’ to ‘almost all the time’) ;

^dRanged from 1 ‘Never’ to 5 ‘Always’ in the past 12 months;

^eRanged from 1 ‘0 times’ to 5 ‘More than 7 times’ in the past 12 months.

Missing values for variables: PET at round 3 (174), PET at round 2 (289), Seeking from non-medical sources (175), patient-clinician information engagement (180), age (1), education (2), health status (115), cancer stage (64), Lerman worry scale (138), followed doctor’s recommendations about tests (157), doctor visits (134), concern about reducing recurrence (126).